Together, these data suggest a role for MRAS, but not reactivation of MAPK signaling (Extended Data Fig. 7e), in driving acquired resistance to adagrasib in KRASG12C-mutated NSCLC cells, and that adagrasib plus BI-3406 combination treatment may be effective within this context. Here, MRAS is linked to non-small cell lung carcinoma.